1. Home
  2. VUZI vs MGNX Comparison

VUZI vs MGNX Comparison

Compare VUZI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vuzix Corporation

VUZI

Vuzix Corporation

N/A

Current Price

$2.44

Market Cap

217.9M

Sector

Technology

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$4.06

Market Cap

256.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VUZI
MGNX
Founded
1997
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
217.9M
256.8M
IPO Year
2009
2013

Fundamental Metrics

Financial Performance
Metric
VUZI
MGNX
Price
$2.44
$4.06
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$5.00
AVG Volume (30 Days)
992.2K
481.4K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
61.11
N/A
EPS
N/A
N/A
Revenue
$6,280,611.00
$149,500,000.00
Revenue This Year
$103.32
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
9.14
N/A
52 Week Low
$1.97
$1.30
52 Week High
$5.62
$5.08

Technical Indicators

Market Signals
Indicator
VUZI
MGNX
Relative Strength Index (RSI) 38.55 48.82
Support Level $2.14 $3.80
Resistance Level $2.66 $4.38
Average True Range (ATR) 0.24 0.20
MACD -0.04 0.00
Stochastic Oscillator 10.40 49.61

Price Performance

Historical Comparison
VUZI
MGNX

About VUZI Vuzix Corporation

Vuzix Corp is engaged in the design, manufacture, and marketing of Artificial Intelligence (AI)-powered Smart Glasses, Waveguides, and Augmented Reality (AR) technologies. Its solutions serve the enterprise, medical, defense, security, and select consumer markets, offering cutting-edge wearable computing and display technologies that enhance productivity and operational efficiency. Its products include near-eye displays (NEDs), heads-up displays (HUDs), and wearable computing devices and third-party original design manufacturer (ODM) and original equipment manufacturer (OEM) devices. Geographically, the company generates a majority of its revenue from the United States and also has a presence in Japan, the Netherlands, and other countries.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: